Medicxi — 2025 Investments

3 investments dated 2025 · listed companies and verified rows first · show all

Rivus Pharmaceuticals, Inc.rivuspharma.com in 𝕏Jan 2025✓ verified

Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US

Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)Allen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)inShaharyar Khan(Co-founder & Chief Scientific Officer)in

Board seatFrancesco De Rubertis· per SEC Form D

Co-investorsBain Capital Life Sciences Longitude Capital RA Capital

Curevo Vaccinecurevovaccine.com inMar 2025 · $110MAcquired

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtechBothell, US

George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in

Board seatGiovanni MariggiMoncef Slaoui· per SEC Form D

Co-investorsAdjuvant Capital HBM Healthcare Investments OrbiMed RA Capital Sanofi Ventures Janus Henderson Investors

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

FORE US Bio

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.